49.78
-0.74 (-1.46%)
Previous Close | 50.52 |
Open | 50.26 |
Volume | 704,085 |
Avg. Volume (3M) | 937,053 |
Market Cap | 3,685,795,584 |
Price / Earnings (TTM) | 1,244.50 |
Price / Sales | 1.99 |
Price / Book | 4.00 |
52 Weeks Range | |
Earnings Date | 6 May 2025 - 12 May 2025 |
Profit Margin | 0.15% |
Operating Margin (TTM) | 6.23% |
Diluted EPS (TTM) | 0.040 |
Quarterly Revenue Growth (YOY) | 13.50% |
Quarterly Earnings Growth (YOY) | -81.70% |
Total Debt/Equity (MRQ) | 152.54% |
Current Ratio (MRQ) | 2.12 |
Operating Cash Flow (TTM) | 233.02 M |
Levered Free Cash Flow (TTM) | 51.06 M |
Return on Assets (TTM) | 2.35% |
Return on Equity (TTM) | 3.99% |
Market Trend
Short Term | Medium Term | ||
Industry | Diagnostics & Research (US) | Bearish | Bearish |
Diagnostics & Research (Global) | Bearish | Bearish | |
Stock | RadNet, Inc. | Bullish | Bullish |
AIStockmoo Score
Analyst Consensus | 4.0 |
Insider Activity | NA |
Price Volatility | 4.5 |
Technical Moving Averages | 0.0 |
Technical Oscillators | 2.0 |
Average | 2.63 |
RadNet Inc is a national provider of diagnostic imaging services that operates in two business segments; The Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures, and Artificial Intelligence segment develops and deploys clinical applications to enhance interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostics. The company derives a majority of its revenue from the Imaging center segment. |
|
Sector | Healthcare |
Industry | Diagnostics & Research |
Investment Style | Small Growth |
% Held by Insiders | 10.43% |
% Held by Institutions | 88.29% |
Ownership
Name | Date | Shares Held |
---|---|---|
Beck Mack & Oliver Llc | 31 Dec 2024 | 3,068,879 |
52 Weeks Range | ||
Price Target Range | ||
High | 74.00 (Truist Securities, 48.65%) | Buy |
Median | 65.00 (30.58%) | |
Low | 60.00 (Barclays, 20.53%) | Buy |
Average | 66.33 (33.25%) | |
Total | 3 Buy | |
Avg. Price @ Call | 52.78 |
Firm | Date | Target Price | Call | Price @ Call |
---|---|---|---|---|
Truist Securities | 11 Apr 2025 | 74.00 (48.65%) | Buy | 53.41 |
Barclays | 24 Mar 2025 | 60.00 (20.53%) | Buy | 51.83 |
Raymond James | 05 Mar 2025 | 65.00 (30.57%) | Buy | 53.09 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2025 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |